Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mesoblast Limited ( (AU:MSB) ) has issued an announcement.
Mesoblast has disclosed a change in director Gregory George’s interests following the lapse of 2.4 million warrants to acquire ordinary shares or ADSs, which expired on 6 January 2026 in line with their terms. The warrants lapsed at no value because the company did not draw down on a previously approved convertible note facility, leaving George with a reduced number of warrants but unchanged holdings in ordinary shares and ADSs; the notice underscores a modest simplification of his derivative exposure without an immediate cash impact on the company or dilution for existing shareholders.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australian biotechnology company focused on developing allogeneic cellular medicines, including stem cell–based therapies, primarily targeting inflammatory diseases, cardiovascular conditions, and other serious and life-threatening illnesses. The company is listed on the ASX and also has American Depositary Shares (ADSs) traded in overseas markets, reflecting a capital structure that includes ordinary shares, ADSs, and various warrant instruments aimed at international biotech investors.
Average Trading Volume: 4,447,733
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.55B
Find detailed analytics on MSB stock on TipRanks’ Stock Analysis page.